Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Sees Significant Decrease in Short Interest

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) was the target of a large decline in short interest in December. As of December 15th, there was short interest totalling 18,100,000 shares, a decline of 7.1% from the November 30th total of 19,490,000 shares. Approximately 24.9% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,090,000 shares, the short-interest ratio is presently 16.6 days.

Day One Biopharmaceuticals Trading Down 2.3 %

DAWN traded down $0.29 during midday trading on Monday, hitting $12.58. The company's stock had a trading volume of 729,024 shares, compared to its average volume of 958,864. Day One Biopharmaceuticals has a 52-week low of $11.94 and a 52-week high of $18.07. The firm has a 50-day moving average price of $13.86 and a two-hundred day moving average price of $14.02. The firm has a market cap of $1.27 billion, a P/E ratio of -12.21 and a beta of -1.51.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last released its earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.58. The company had revenue of $93.76 million during the quarter, compared to analysts' expectations of $15.05 million. During the same quarter in the previous year, the firm posted ($0.54) earnings per share. On average, equities analysts expect that Day One Biopharmaceuticals will post -0.88 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on DAWN shares. Needham & Company LLC reissued a "buy" rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. TD Cowen upgraded shares of Day One Biopharmaceuticals to a "strong-buy" rating in a report on Monday, November 4th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $35.71.

Insider Buying and Selling

In related news, insider Samuel C. Blackman sold 30,000 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $13.31, for a total transaction of $399,300.00. Following the completion of the transaction, the insider now directly owns 1,034,015 shares in the company, valued at $13,762,739.65. The trade was a 2.82 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold 51,745 shares of company stock worth $748,567 in the last three months. Corporate insiders own 8.40% of the company's stock.

Institutional Trading of Day One Biopharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in DAWN. Franklin Resources Inc. grew its holdings in shares of Day One Biopharmaceuticals by 2.3% during the 3rd quarter. Franklin Resources Inc. now owns 3,869,632 shares of the company's stock worth $55,336,000 after purchasing an additional 87,262 shares during the period. Geode Capital Management LLC lifted its position in Day One Biopharmaceuticals by 10.5% during the third quarter. Geode Capital Management LLC now owns 1,432,697 shares of the company's stock valued at $19,961,000 after buying an additional 136,458 shares in the last quarter. Frazier Life Sciences Management L.P. purchased a new stake in Day One Biopharmaceuticals during the third quarter worth approximately $9,607,000. XTX Topco Ltd acquired a new stake in shares of Day One Biopharmaceuticals in the third quarter worth $178,000. Finally, Wellington Management Group LLP lifted its holdings in shares of Day One Biopharmaceuticals by 142.1% during the 3rd quarter. Wellington Management Group LLP now owns 721,581 shares of the company's stock valued at $10,052,000 after acquiring an additional 423,543 shares in the last quarter. 87.95% of the stock is currently owned by institutional investors and hedge funds.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.